For the students of Bioinformatics course
Immunology and Molecular Pathology
The classroom for the course is located in:
Psicologia I, Fisiologia Generale e Antropologia Farmacia e Medicina (CU026, E01PSIL101)
In order to follow the lesson remotely, you will need to connect using Zoom and the link is posted in E-learning
Giovedì 14.00-16.00 o previo appuntamento
Date of birth: June, 16 1970
Position title: Assistant Professor
Work address: Department of Molecular Medicine, University
of Rome La Sapienza . V.le Regina Elena, 291 00161- Rome, Italy
1994 Graduated with honors in Biology. University of Rome La Sapienza .
1996 National Board for biologists.
1999 PhD in Immunological Science, University of Rome La Sapienza .
Since 2008, I had the opportunity to lead small research groups composed at first by undergraduate and PhD students, and more recently also by post-doctoral fellows. I have been awarded a grant as associated investigator in FIRB Futuro in Ricerca for years 2010-2014 from the Ministry of Education, University and Research (MIUR), Sapienza University funded grants in years 2014 and 2016-2017 and I participated to several projects funded by the Italian Association for Cancer Research (AIRC). The project results and the collaboration undertaken with other research groups allowed the publication of several original articles in high impact factor journals including Blood, Cancer Research and Nature Communications and allowed the discovery of the chemokine role in the regulation of NK cell subset trafficking in bone marrow and how this affect diseases, i.e. multiple myeloma, osteoarthritis and WHIM syndrome.
My group is currently composed by one PhD student, and one research fellow, working on NK cell-based anti-tumor therapeutic approaches based on chemokine receptor targeting. A second ongoing field of investigation concerns the analysis of the role of CXCR4 in NK cell development using in vitro differentiation assays and analyzing the phenotype of NK cells in mice bearing a CXCR4 mutation described in the WHIM syndrome, a rare disease that leads to CXCL12 hyperresponsiveness All team members have expertise in molecular biology, cell biology, and immunology techniques and have been trained for animal care.
Positions and Employment
1995-1998 Research Fellow at the Regina Elena Cancer Institute, CRS
1998-1999 Research Fellow, Laboratory of Vascular Pathology. Istituto
Dermopatico dell' Immacolata - IRCCS Roma, Italy
2000-2001 Post-doctoral fellow Lab of Immunology and Vascular Biology
Stanford University Medical School. Director: Prof. Eugene C. Butcher.
Jan-Nov 2002 Post-doctoral fellow in the Laboratory of Immunology, Department of
Experimental Medicine and Pathology, University of Rome La Sapienza .
2002-2017 Assistant Professor, at the Dept of Experimental Medicine and since 2010 at
the Department of Molecular Medicine, University of Rome La Sapienza
2015-present Consultant, IRCCS Neuromed, Pozzilli (IS), Italy
2018- Associate Professor, at the Department of Molecular Medicine, University of Rome La Sapienza
2000-2001 Winner of One-year Scholarship for research abroad of Italian Federation for
Cancer Research (FIRC)
2001 Winner of One-year Scholarship for research abroad of The Foundation
Blanceflor Boncompagni-Ludovisi of Sweden
2003-present Teaching in Immunology in the Biotechnology Course (2CFU) at University of Rome La Sapienza
2004-present Lecturer in the immunology course at the Faculty of Medicine of University
of Rome La Sapienza .
2008-2017 Member of the teaching body for the evaluation of PhD students (PhD school
in Immunological, Hematological and Rheumatological Sciences).
2018- Professor of Immunology and Immunopathology at the Bioinformatics Course (6CFU) at the University of Rome La Sapienza.
Memberships in Professional Societies
SIICA (Società Italiana di Immunologia, Immunologia Clinica e Allergologia)
Peer review activity
Review Editor in Frontiers in Immunology
Oral communication in national and international Meeting and Workshop
- Meeting of Societa Italiana di Immunologia Clinica e Allergologia (SIICA).CXCL12 and CCL3 regulate trafficking of developing mouse bone marrow NK cells. Trieste Italy. 2007
-2° Workshop Chemokines and Chemokine receptors in the nervous system. CX3CL1/CX3CR1 axis in neural and immune cell functions. Rome, Italy. 2009
- XXX National Congress of Italian Society of Pathology. KLRG1+ NK cells include two distinct populations lined by CX3CR1 expression. Salerno, Italy. 2010
Workshop Immune cell interactions: a mechanism for immune system control. Different requirement of chemokine receptor for natural killer cell subset trafficking to the bone marrow June 8th, 2012. SOFIA, BULGARIA
10th International Veterinary Immunology Symposium 2013. Regulation of mouse NK cell trafficking in bone marrow by chemokine/chemokine receptor axes. Milan, Italy. 2013
Day of Immunology in Rome. Multiple myeloma impairs localization of effector NK cells in the
bone marrow. Rome, Italy. 2015
Contribution to Science
Giovanni Bernardini s scientific interest, which overlaps with the proposed research, is to elucidate the factors that regulate NK cell trafficking into tissues underneath of human inflammatory and tumor pathologies using animal models and patient s samples, and to propose novel therapeutic strategies.
Scientific activities 1995-2000: Identification and functional characterization of new chemokine receptors: Involved in cloning of the human chemokine receptor CCR8 ORF and in the identification of its human and viral ligands (publ. 1-3). In addition, he contributed to the cloning of the ORF of other GPCRs and to their genetic and functional characterization. In collaboration with the laboratories of Prof. Ziche in Firenze e of Prof. Ribatti in Bari he demonstrated that I-309, a CCR8 ligand, stimulates chemotaxis and invasion of endothelial cells, enhances HUVEC differentiation and induces angiogenesis in vivo (publ. 4).
Scientific activity 2000-2004: Analysis of signalling events involved in LFA-1-dependent lymphocyte migration in response to chemotactic molecules: Visiting scholar in the Laboratory directed by Prof. Eugene C. Butcher at Stanford University. In that period and in a subsequent period in Rome he was interested in the analysis of signal transduction pathway activated by chemokines leading to integrin activation. The results of this activity have shown that chemoattractant-induced LFA-1 dependent migration is regulated by PI 3K activation and that a Fyn-PI 3K-LFA-1 molecular complex has to be formed to promote cell migration (publ. 5)
Scientific activity 2004-2009: Role of chemokines in the regulation of tumor cell invasive capacity. He was responsible of a project aimed at analyzing the role of chemokines in human glioma cell invasiveness. His results indicate that endogenous expression of CX3CL1 by glioma cells is controlled by TGF-beta1 and negatively regulates glioma cell invasion likely by promoting tumor cell aggregation (publ. 7).
Scientific activity 2006-present: Analysis of the mechanisms regulating NK cell migration and function in vivo in homeostasis, cancer, inflammation: He is mainly interested in the molecular mechanisms regulating mouse NK cell trafficking and differentiation in the bone marrow. Using in vivo mouse models, he previously analyzed changes in NK cell distribution following stimuli that affect chemokine receptor function. The results of his studies suggest that the combined action of chemokines selectively regulates localization of NK cell subsets in the BM and direct their maturation and migration to the periphery (publ. 6, 9-12). He showed that the action of chemokines in BM is regulated by multiple myeloma, a hematological tumor growing in BM, to influence the BM retention capacity of NK cells and evade NK cell immune surveillance (17, 22).
He recently started a study of the factors produced in MM microenvironment able to suppress NK cell anti-tumor function, particularly focusing on those that are produced by myeloid suppressor cells. Thanks to a collaboration with the group of P. Dimitrova (Stefan Angelov Institute of Microbiology, Sofia, Bulgaria) and P. van Lent (Radbound University Nijmegen, The Netherlands), he also characterized the role of inflammatory chemokines, in particular CXCL10, and how they interact with NK cells in the progression of osteoarthritis using mouse models (publ. 20, 21).
Associated investigator in FIRB Futuro in Ricerca 2010 (years 2010-2014) and recipient of several project funds (years 2004, 2010, 2013, 2015) from Sapienza University. Recipient of project funds from Institute Pasteur Italia Fondazione Cenci Bolognetti (years 2018-2019).
Participant in several projects funded by Italian Association for Cancer Research (AIRC) and by Ministry of Education, University and Research (MIUR).
Published articles: 45
Book chapter: 2
Articles in press: 1
H index: 22
Last 10-year publications:
1. Bernardini G, Sciume G, Bosisio D, Morrone S, Sozzani S, Santoni A. CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets. Blood. 2008 111(7):3626-34
2. Sciumè G, Soriani A, Piccoli M, Frati L, Santoni A, Bernardini G. CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. Neuro-oncology, 2010; 12: 701-710
3. Sciumè G, Santoni A, Bernardini G. Chemokines and glioma: Invasion and more. Journal of Neuroimmunol., 2010; 224: 8-12
4. Sciumè G, De Angelis G, Benigni G, Morrone S, Santoni A, Bernardini G. CX3CR1 expression defines two KLRG1+ mouse NK cell subsets with distinct functional properties and positioning in the Bone Marrow. Blood. 2011; 117:4467-75
5. Bernardini G, Gismondi A, Santoni A. Chemokines and NK cells: Regulators of Development, Trafficking and Functions. Immunology Letters. 2012; 145: 39 46
6. Bernardini G, Sciumè G, Santoni A. Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow. Front Immunol. 2013;4:12
7. Ponzetta A, Sciumè G, Benigni G, Antonangeli F, Morrone S, Santoni A, Bernardini G. CX3CR1 regulates the maintenance of KLRG1+ NK cells into the bone marrow by promoting their entry into circulation. J Immunol. 2013;191(11):5684-94.
8. Bernardini G, Benigni G, Antonangeli F, Ponzetta A, Santoni A. Multiple levels of chemokine receptor regulation in the control of mouse natural killer cell development. Frontiers in Immunol. 2014; 5: 44
9. Bernardini G. and Santoni, A. The Pathophysiological Role of Chemokines in the Regulation of NK Cell Tissue Homing Critical Reviews in Oncogenesis 2014;19: 77-90
10. Paolini R, Bernardini G, Molfetta R, Santoni A. NK cells and interferons Cytokine Growth Factor Rev. 2015; 26(2):113-20
11. Garofalo S, D Alessandro G, Chece G, Frederic Brau, Maggi L, Rosa A, Porzia A, Mainiero F, Esposito V, Lauro C, Benigni G, Bernardini G, Santoni A, Limatola C. Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice. Nat Commun. 2015;6:6623.
12. Ponzetta A, Benigni G, Antonangeli F, Sciumè G, Sanseviero E, Zingoni A, Ricciardi MR, Petrucci MT, Santoni A, Bernardini G. Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment. Cancer Res. 2015;75(22):4766-77.
13. Antonangeli F, Soriani A, Ricci B, Ponzetta A, Benigni G, Morrone S, Bernardini G, and Santoni A. Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells. OncoImmunology . 2016; Vol. 5 (10). dx.doi.org/10.1080/2162402X.2016.1218105
14. Bernardini G, Antonangeli F, Bonanni V, Santoni A. Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases. Front Immunol. 2016; 7:402.
15. Nabissi M, Morelli MB, Cardinali C, Santoni M, Arcella A, Bernardini G, Santoni A, Santoni G, and Amantini C. Post-transcriptional regulation of 5'-untranslated regions of human Transient Receptor Potential Vanilloid type-1 (TRPV-1) channels: role in the survival of glioma patients. Oncotarget 2016 Nov 5. doi: 10.18632/oncotarget.13132.
16. Morelli MB, Amantini C, Nabissi M, Cardinali C, Santoni M, Bernardini G, Santoni A, Santoni G. Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner. Oncotarget. Jan 10;8(2):3380-3395. doi: 10.18632/oncotarget.13769.
17. Benigni G, Dimitrova P, Antonangeli F, Sanseviero E, Milanova V, Blom A, van Lent P, Morrone S, Santoni A, Bernardini G. CXCR3/CXCL10 Axis Regulates Neutrophil-NK Cell Cross-Talk Determining the Severity of Experimental Osteoarthritis. J Immunol. 2017 Mar 1;198(5):2115-2124.
18. Bernardini G, Vulpis E, Bonanni V, Stabile H, Ricciardi MR, Petrucci MT, Gismondi A, Santoni A, Zingoni A. High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma. Leuk Lymphoma. 2017;58(10):2493-2496
19. Bernardini G, Benigni G, Scrivo R, Valesini G, Santoni A. The Multifunctional Role of the Chemokine System in Arthritogenic Processes. Curr Rheumatol Rep. 2017;19(3):11
20. Molgora M., Bonavita E, Ponzetta A, Riva F, Barbagallo M, Jaillon S, Popovi B, Bernardini G, Elena Magrini E, Gianni F, Zelenay S, Jonji S, Santoni A, Garlanda C and Mantovan A. IL-1R8 is a checkpoint in NK cells regulating anti-tumor and anti-viral activity. Nature 2017; 551(7678):110-114
21. Garofalo S, Porzia A, Mainiero F, Di Angelantonio S, Cortese B, Basilico B, Pagani F, Cignitti G, Chece G, Maggio R, Tremblay ME, Savage J, Bisht K, Esposito V, Bernardini G, Seyfried T, Mieczkowski J, Stepniak K, Kaminska B, Santoni A, Limatola C. Environmental stimuli shape microglial plasticity in glioma. Elife. 2017;6. pii: e33415. doi: 10.7554/eLife.33415.
22. Soriani A, Stabile H, Gismondi A, Santoni A, Bernardini G. Chemokine regulation of innate lymphoid cell tissue distribution and function. Cytokine Growth Factor Rev. 2018 Feb 14. pii: S1359-6101(18)30014-5. doi: 10.1016/j.cytogfr.2018.02.003. Review.
23. Giorgio Santoni, Consuelo Amantini, Maria Beatrice Morelli, Daniele Tomassoni, Matteo Santoni, Oliviero Marinelli, Massimo Nabissi, Claudio Cardinali, Vittorio Paolucci, Mariangela Torniai, Silvia Rinaldi, Francesca Morgese, Giovanni Bernardini and Rossana Berardi. High CTLA-4 expression correlates with poor prognosis in thymoma patients Oncotarget. 2018 https://doi.org/10.18632/oncotarget.24645
24. Fionda C, Stabile H, Molfetta R, Soriani A, Bernardini G, Zingoni A, Gismondi A, Paolini R, Cippitelli M, Santoni A. Translating the anti-myeloma activity of Natural Killer cells into clinical application. Cancer Treat Rev. 2018 Nov;70:255-264. doi: 10.1016/j.ctrv.2018.10.005.
25. Ferrandino F, Bernardini G, Tsaouli G, Grazioli P, Campese AF, Noce C, Ciuffetta A, Vacca A, Besharat ZM, Bellavia D, Screpanti I, Felli MP. Intrathymic Notch3 and CXCR4 combinatorial interplay facilitates T-cell leukemia propagation. Oncogene. 2018 Dec;37(49):6285-6298. doi: 10.1038/s41388-018-0401-2.
26-Bonanni V, Antonangeli F, Santoni A, Bernardini G Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells J IMMUNOTHER CANCER 2019 Nov; 7: 290
27- Del Prete A, Sozio F, Schioppa T, Ponzetta A, Vermi W, Calza S, Bugatti M, Salvi V, Bernardini G, Benvenuti F, Vecchi A, Bottazzi B, Mantovani A, Sozzani The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance. S CANCER IMMUNOL RES 2019 Nov; 7: 1775-1788
28-Bernardini G, Zabel BA Editorial: The Role of Chemoattractants in the Tumor Microenvironment. Front Immunol 2019; 10: 2671
29-Bonanni V, Sciumè G, Santoni A, Bernardini G Bone Marrow NK Cells: Origin, Distinctive Features, and Requirements for Tissue Localization. Front Immunol 2019; 10: 1569
30-Garofalo S, Cocozza G, Porzia A, Inghilleri M, Raspa M, Scavizzi F, Aronica E, Bernardini G, Peng L, Ransohoff R, Santoni A, Limatola C. Natural killer cells modulate motor neuron-immune cell cross talk in models of Amyotrophic Lateral Sclerosis. NATURE COMMUNICATIONS. - 1:11(2020), pp. 1773-1788.
|Natural killer cells modulate motor neuron-immune cell cross talk in models of amyotrophic lateral sclerosis||NATURE COMMUNICATIONS||2020|
|Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer||JOURNAL OF LEUKOCYTE BIOLOGY||2020|
|The atypical receptor CCRL2 is essential for lung cancer immune surveillance||CANCER IMMUNOLOGY RESEARCH||2019|
|Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells||JOURNAL FOR IMMUNOTHERAPY OF CANCER||2019|
|Bone Marrow NK Cells: Origin, Distinctive Features, and Requirements for Tissue Localization||FRONTIERS IN IMMUNOLOGY||2019|
|Editorial: the role of chemoattractants in the tumor microenvironment||FRONTIERS IN IMMUNOLOGY||2019|
|Chemokine regulation of innate lymphoid cell tissue distribution and function||CYTOKINE & GROWTH FACTOR REVIEWS||2018|
|Intrathymic Notch3 and CXCR4 combinatorial interplay facilitates T-cell leukemia propagation.||ONCOGENE||2018|
|High CTLA-4 expression correlates with poor prognosis in thymoma patients||ONCOTARGET||2018|
|Notch3 and CXCR4 cross-signaling sustains acute T-cell leukemia progression||ESMO OPEN||2018|
|Translating the anti-myeloma activity of Natural Killer cells into clinical application||CANCER TREATMENT REVIEWS||2018|
|Insegnamento||Codice||Anno||Corso - Frequentare|
|IMMUNOLOGY AND MOLECULAR PATHOLOGIES||1049260||2020/2021||Bioinformatics - Bioinformatica|
|IMMUNOLOGIA ED IMMUNOPATOLOGIA - PATOLOGIA MOLECOLARE E CELLULARE||10596057||2020/2021||Biotecnologie mediche|
|IMMUNOLOGY AND MOLECULAR PATHOLOGIES||1049260||2019/2020||Bioinformatics|
|IMMUNOLOGY AND MOLECULAR PATHOLOGIES||1049260||2018/2019||Bioinformatics|
|IMMUNOLOGY AND MOLECULAR PATHOLOGIES||1049260||2017/2018||Bioinformatica|